Consensus Statement on 21-Hydroxylase Deficiency from The Lawson Wilkins Pediatric Endocrine Society and The European Society for Paediatric Endocrinology
The DOI matches its Crossref record.
Abstract
Despite over 50 yr of experience with steroid replacement therapy, the management of congenital adrenal hyperplasia (CAH) remains difficult, and clinical practice varies substantially throughout the world. To consider the evidence for best practice, to formulate management guidelines, and to consider innovative therapies, The Lawson Wilkins Pediatric Endocrine Society (LWPES) and The European Society for Pediatric Endocrinology (ESPE) convened a meeting in Gloucester, MA, March 14–17, 2002. The 40 participating physicians, psychologists, scientists, and surgeons from 12 countries on 4 continents agreed with the following consensus statement; this statement is concerned exclusively with CAH caused by 21-hydroxylase deficiency and does not address the other, rarer forms of CAH. The newborn female with CAH and ambiguous external genitalia requires urgent expert medical attention. The ambiguity is highly distressing to the family; therefore, immediate comprehensive evaluation is needed by referral to, or a visit by, a pediatric endocrinologist. An important goal is to ensure that the parents develop a positive relationship with their child. A well-organized multidisciplinary team (including specialists in pediatric endocrinology, psychosocial services, pediatric surgery/urology, and genetics) is essential for the diagnosis and management of the infant with ambiguous genitalia. It is important that the coordinator of the team has experience in the long-term care of the patient with CAH and provides a consistent message to the parents. Every newborn with ambiguous genitalia, a suspected diagnosis of CAH, or an abnormal result in a newborn screen for 17-hydroxyprogesterone (17OHP) should be evaluated by a pediatric endocrinologist. The evaluation of an infant with ambiguous genitalia includes a complete history, a physical examination, a reliable ultrasound investigation of the internal genitalia and adrenals, karyotype or fluorescence in situ hybridization for sex chromosome material, and a rapid, reliable plasma or serum measurement of 17OHP. Premature newborns may need serial measurements of 17OHP to differentiate false positive results from affected infants with CAH. Neonatal mass screening for 21-hydroxylase deficiency identifies both male and female affected infants, prevents incorrect sex assignment, and decreases mortality and morbidity (1–4). Therefore, newborn screening for CAH is beneficial and is recommended. Newborn screening is sufficiently specific and sensitive to detect almost all infants with classical CAH and some infants with nonclassical CAH (NCCAH). Sampling of blood spots should be performed, ideally between 48 and 72 h of age, and sent to the screening laboratory without delay. At present, direct binding assays for blood-spot 17OHP are the only practical method for screening. Each screening laboratory needs to establish validated cut-off levels related to gestational age and birth-weight, because 17OHP levels decline with increasing gestational age. Only laboratories with excellent internal and external quality control, demonstrated accuracy, and a rapid turn-around time on a large number of samples should be used. The laboratory should report immediately any abnormal result to the physician responsible for the patient. A reliable CAH screening program requires both clinical evaluation and laboratory investigation for diagnostic confirmation. A positive screening result needs to be confirmed either by a validated 17OHP measurement of a second serum/plasma sample, a urine sample for a steroid profile, or analysis of the CYP21 gene. Newborn screening, using 17OHP, may detect other forms of CAH. In uncertain cases, additional specific tests are required. Measurements of androstenedione, aldosterone, cortisol, and testosterone by direct immunoassays are of limited value for diagnosis in the newborn. Molecular genetic analysis is not essential for the diagnosis but may be helpful to confirm the basis of the defect, to aid in genetic counseling, and to establish the diagnosis in uncertain cases. Ten mutations account for 90–95% of the affected alleles, but molecular genetic analysis is complicated by multiple copies of the genes and the possibility of multiple mutations on one allele (5, 6). The clinical features may not correlate with the genetic mutation in a small percentage of cases. Parental DNA samples are essential to segregate alleles. Salt wasters may not be apparent in the first days, or even weeks, after birth by electrolyte measurements. Salt wasters may be differentiated from simple virilizers by serial serum/plasma and/or urine electrolytes, plasma renin activity (PRA) or direct renin, and the results of CYP21 molecular analysis. Prenatal treatment has been advocated for fetuses at risk for classic CAH but is not appropriate for nonclassic CAH. The appropriateness, ethics, and outcomes of the prenatal treatment of CAH with dexamethasone remain controversial (7, 8). However, based on
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Life-long treatment with glucocorticoids will restore any cortisol deficiency and suppress ACTH secretion and subsequent androgen production (27).”
From ACTH Antagonists (2016) · cites this paper as [27]
In the citing paper
“21-Hydroxylase deficiency, caused by mutations in P450c21, is the most common form of CAH and one of the most common inborn errors of metabolism.”
From The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders (2011) · cites this paper as [408]
In the citing paper
“After appropriate fluid resuscitation, the mineralocorticoids and glucocorticoids can be replaced orally, and the ambiguous genitalia can be corrected with a series of plastic surgical procedures, but the management is complicated and difficult (408, 410).”
From The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders (2011) · cites this paper as [408]
Citations
Cites
Still being checked.
Cited by
Items 301–329 of 329
Endokrinologische Erkrankungen
(2011) · Elsevier eBooks · doi:10.1016/b978-3-437-22702-8.50013-3
Pirazzoli, P., & Cicognani, A. (2012) · Springer eBooks · doi:10.1007/978-88-470-2059-7_51
Karkazis, K. (2008) · Duke University Press eBooks · doi:10.1215/9780822389217-010
Karkazis, K. (2008) · Duke University Press eBooks · doi:10.1215/9780822389217-012
Disorders of Sexual Development in Newborns
Balsamo, A., Ghirri, P., Bertelloni, S., Scaramuzzo, R. T., D’Alberton, F., Cicognani, A., & Boldrini, A. (2017) · Springer eBooks · doi:10.1007/978-3-319-18159-2_260-2 · Cited by 1
Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency)
(2006) · Humana Press eBooks · doi:10.1007/978-1-60327-161-5_37
Wass, J. A. H., Owen, K. R., & Turner, H. E. (2014) · Oxford University Press eBooks · doi:10.1093/med/9780199644438.003.0004
Willenberg, H. S. (2016) · Springer eBooks · doi:10.1007/978-3-642-54676-1_27-1
Epicardial fat thickness in children with classic congenital adrenal hyperplasia
Metwalley, K. A., Farghaly, H. S., & Abdelhamid, A. (2018) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.0153
(2009) · CRC Press eBooks · doi:10.1201/9781420079364.ch7
(2022) · American Registry of PathologyArlington, Virginia eBooks · doi:10.55418/9781933477251-4
Fernández, M. S., Sitja, M. M., González-Pinto, L. C., Arteta, E. L. H., & Sánchez, A. R. (2023) · Hormone and Metabolic Research · doi:10.1055/a-2111-6571 · Cited by 1
EVALUATION OF FINAL HEIGHT IN PATIENTS WITH CONGENITAL ADRENAL HYPERPLASIA
Kurtipek, F. B., Keskın, M., Bayramoğlu, E., & Aycan, Z. (2024) · Pamukkale Medical Journal · doi:10.31362/patd.1366476
Update in Pediatric Endocrinology
Marks, S. D., & Wicklow, B. A. (2023) · Springer eBooks · doi:10.1007/978-3-031-41542-5_14
D'El-Rey, Z. M. B. A. (2024) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2024.tde-29072024-103612
Newborn Screening in India: A Systematic Review and Meta-AnalysisPreprint
Chauhan, M., Mahendru, A., Bhardwaj, A., Suravajhala, P., Kapoor, S., & Polipalli, S. K. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.5051990 · Cited by 1
Update on prenatal diagnosis and treatment of congenital adrenal hyperplasia
Westeinde, A. V., Nordenström, A., & Lajić, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00183-7
Akyürek, N., Eklioğlu, B. S., Atabek, M. E., Alp, H., & Gün, H. (2025) · Cardiology in the Young · doi:10.1017/s1047951124036576
Corticosteroids in Pediatric Endocrinology
Giannini, C., & Mohn, A. (2015) · Springer eBooks · doi:10.1007/978-3-319-16056-6_11
Massuqueto, E., Venturini, B. A., de Moura, I. M. S., Oliveira, L. M. B., Farias, J. A. D., Arruti, R. A., Amorim, T., Rodrigues, M. L. B., Pinheiro, J. T., Castro, A. F., et al. (2026) · Journal of Pediatric Urology · doi:10.1016/j.jpurol.2026.105797
Abıke, F., Tanoğlu, F. B., & Sammour, B. (2026) · Journal of Gynecology Obstetrics and Human Reproduction · doi:10.1016/j.jogoh.2026.103134
Male sex assignment in severely virilized 46,XX children with congenital adrenal hyperplasia
Beniczky, N. J., Magyar, E. L., Sallai, Á., Jenővári, Z., Sükösd, Z., Vajda, Z., Steenkamp, Y.-L., Szücs, N., & Bertalan, R. Á. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1765653
Gawlik, Z., Gawlik, J., Tyrawa, K., Starzyk, J., & Januś, D. (2026) · European Journal of Pediatrics · doi:10.1007/s00431-026-07454-9
Auffälliges Genitale sowie beschleunigtes Längenwachstum und Knochenalter
Schreiner, F., Woelfle, J., Lentze, M. J., & Gohlke, B. C. (2007) · Monatsschrift Kinderheilkunde · doi:10.1007/s00112-007-1599-1
Définition et classification des maladies héréditaires du métabolisme
Thervet, É. (2013) · Références en médecine d'urgence · doi:10.1007/978-2-8178-0350-0_3
Metadata
- Authors
- Joint LWPES/ESPE CAH Working Group
- Corresponding author
- Joint LWPES/ESPE CAH Working Group
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2002-09
- Volume
- 87
- Issue
- 9
- Pages
- 4048-4053
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W4234360283
- Cited by
- 332
- References
- 0
- Citations by year
- 2026: 5 · 2025: 2 · 2024: 10 · 2023: 3 · 2022: 6 · 2021: 9 · 2020: 9 · 2019: 15 · 2018: 17 · 2017: 9 · 2016: 13 · 2015: 12 · 2014: 13 · 2013: 22 · 2012: 17
- FWCI
- 4.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Funders
- European Society for Paediatric Endocrinology
- European Society of Endocrinology
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Keywords
- 21-hydroxylase deficiency, congenital adrenal hyperplasia, ambiguous genitalia, newborn screening, 17-hydroxyprogesterone, steroid replacement therapy, cortisol, fludrocortisone, glucocorticoid therapy, multidisciplinary care, gender assignment, psychosocial support
- MeSH terms
- Adrenal Hyperplasia, Congenital, Adrenalectomy, Female, Glucocorticoids, Humans, Pregnancy, Prenatal Diagnosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.